WM

Live from ASCO 2023 | Ascentage Pharma Releases the First Dataset of Lisaftoclax in WM, Revealing Encouraging Therapeutic Potential

Retrieved on: 
Tuesday, June 6, 2023
Armed Forces Radiobiology Research Institute, Neutropenia, PK, Rituximab, Mayo Clinic, CXCR4, Diarrhea, Arm, TLS, Aes, DLT, Cancer, DDI, Pharmacokinetics, Mutation, CHB, MTTR, Appetite, Abdominal pain, WM, ASCO, Kidney, American Society of Clinical Oncology, Patient, Risk, Anemia, Apoptosis, Annual general meeting, Tumor lysis syndrome, Nausea, MTD, Bone marrow, Poster, Principal, Leukopenia, Notifiable disease, Society, Thrombocytopenia, ORR, Hepatitis, Safety, Common, Pharmaceutical industry, MD

"In this global Phase Ib/II study, lisaftoclax monotherapy showed encouraging antitumor activity and satisfactory safety profile in patients with relapsed/refractory (R/R) WM who had received prior treatment with BTKis.

Key Points: 
  • "In this global Phase Ib/II study, lisaftoclax monotherapy showed encouraging antitumor activity and satisfactory safety profile in patients with relapsed/refractory (R/R) WM who had received prior treatment with BTKis.
  • This drug's other attributes include the patient friendly daily dose ramp-up schedule which allows for faster attainment of target therapeutic doses.
  • "In particular, the lisaftoclax plus BTKi regimen has demonstrated an impressive ORR that signalled exciting clinical potential.
  • Appendix: The four posters on Ascentage Pharma's four lead drug candidates, including lisaftoclax, presented at this year's ASCO Annual Meeting.

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference

Retrieved on: 
Friday, May 26, 2023
TKI, CXCR4, PD, Cohort, SDH, Arrhythmia, Patient, AST, Landing slot, Thrombocytopenia, Fatigue, Disease, ALK, GIST, Male, PRS, Diarrhea, Arm, Pharmacokinetics, Mutation, Vomiting, ALT, Leukopenia, PR, Safety, Neutropenia, AE, Pulmonary embolism, Dehydration, Aes, DLT, DDI, Multimedia, NSCLC, MTTR, Immunotherapy, CBR, Anemia, CR, FAK, Pembrolizumab, ORR, Joint effusion, Electrolyte, Armed Forces Health Longitudinal Technology Application, PK, Rituximab, PM, Phosphorylation, IO, DCR, TLS, Weight loss, Trae tha Truth, Septic shock, WM, Thrombosis, Kidney, Nausea, AM, Recurrence, SD, QOD, Female, Powder metallurgy, Pharmaceutical industry, Nursing, PBMC

As of December 9, 2022, 130 patients were enrolled and treated with APG-2449 at doses ranging from 900 to1,500 mg.

Key Points: 
  • As of December 9, 2022, 130 patients were enrolled and treated with APG-2449 at doses ranging from 900 to1,500 mg.
  • Meanwhile, patients with higher pFAK expression in tumor tissues at baseline tended to achieve better clinical responses than those with lower pFAK expression after APG-2449 treatment.
  • Efficacy Results: The median duration of treatment in the 20 patients with SDH-deficient GIST was 7.8 (1.81-42.3) months.
  • Conclusions: Alrizomadlin combined with pembrolizumab is well tolerated and demonstrates clinical efficacy in patients with cutaneous melanoma that had progressed on PD-1/PD-L1 immunotherapy.

Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates

Retrieved on: 
Thursday, May 18, 2023
Waldenström macroglobulinemia, Partnership, City of Hope, Mayo Clinic, Employment, Birmingham School of Law, Malignancy, University, GBM, CD20, Fred Hutchinson Cancer Research Center, Neoplasm, Biotechnology, Lead, University of Massachusetts Chan Medical School, Translation, Sale, WM, Security, CAR, PSCA, CDMO, Hematological Cancer Research Investment and Education Act, City, Waldenström, Acquisition, CGMP, Patient, Cancer, XSCID, Birmingham, Ecosystem, Nationwide, Mustang, IND, DSM-IV codes, Leiden University, Vaccine, Bank, Pharmaceutical industry, Fine chemical, Greater Boston

WORCESTER, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.

Key Points: 
  • Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology.
  • Additionally, Mustang announced a partnership with uBriGene (Boston) Biosciences Inc. (“uBriGene”), the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization (“CDMO”), which includes the sale of the Company’s development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene.
  • Subject to closing, the parties will enter into a manufacturing supply agreement, under which uBriGene will manufacture Mustang’s lead product candidates, including continuing to support MB-106 manufacturing for the ongoing multi-center Phase 1/2 trial.
  • I want to thank our manufacturing team for their dedication in building and growing our Worcester facility since it opened in 2018.

Wildman Business Group acquires WM Uniform

Retrieved on: 
Wednesday, May 17, 2023
Other Manufacturing, Manufacturing, Textiles, Maintenance, Partnership, Culture, Eye, WM, Organization, Name, Retirement, Acquisition, Growth, Region, Safety, Management

Wildman Business Group, based in Warsaw, Indiana, announced today the acquisition of WM Uniform, located in Holland, Michigan.

Key Points: 
  • Wildman Business Group, based in Warsaw, Indiana, announced today the acquisition of WM Uniform, located in Holland, Michigan.
  • Together the combined entity operates from six locations throughout Indiana and Michigan with 440 employees, serving more than 12,000 customers.
  • “The opportunity to come together was driven by President of WM Uniform, Patrick Van Tuinen’s eye toward succession planning and was made easy with alignment on our shared core values around honesty, integrity, relationships, excellence, living by faith, and treating others as they would want to be treated,” said Josh Wildman, CEO of Wildman Business Group.
  • “We are stronger together,” said Josh Wildman, CEO of Wildman Business Group.

AvAir Receives Airline Economics Sustainability Award

Retrieved on: 
Wednesday, May 17, 2023
Taiwan Corporate Sustainability Awards, WM, ASA, Virtual airline (economics), ISO 9001, Transport, Oropharyngeal airway, Carbon, Water, Airline, Online shopping

CHANDLER, Ariz., May 17, 2023 /PRNewswire/ --  AvAir, an industry-leading inventory solutions provider for the aviation aftermarket, has been awarded for its sustainability efforts by Airline Economics, the leading industry trade publication, and received this year's Sustainability Award.

Key Points: 
  • CHANDLER, Ariz., May 17, 2023 /PRNewswire/ -- AvAir , an industry-leading inventory solutions provider for the aviation aftermarket, has been awarded for its sustainability efforts by Airline Economics, the leading industry trade publication, and received this year's Sustainability Award.
  • AvAir is working with the leading environmental service and solutions provider in North America, WM to invest, improve and build upon its sustainability strategy and endeavor.
  • "The aviation industry has a great opportunity to make changes to support green initiatives and expand our sustainable practices," said Mike Bianco, CEO of AvAir.
  • Following that, AvAir will establish goals and initiatives to continue to improve its environmental impact across all channels of the company.

AvAir Receives Airline Economics Sustainability Award

Retrieved on: 
Wednesday, May 17, 2023
Taiwan Corporate Sustainability Awards, WM, ASA, Virtual airline (economics), ISO 9001, Transport, Oropharyngeal airway, Carbon, Water, Airline, Online shopping

CHANDLER, Ariz., May 17, 2023 /PRNewswire/ --  AvAir, an industry-leading inventory solutions provider for the aviation aftermarket, has been awarded for its sustainability efforts by Airline Economics, the leading industry trade publication, and received this year's Sustainability Award.

Key Points: 
  • CHANDLER, Ariz., May 17, 2023 /PRNewswire/ -- AvAir , an industry-leading inventory solutions provider for the aviation aftermarket, has been awarded for its sustainability efforts by Airline Economics, the leading industry trade publication, and received this year's Sustainability Award.
  • AvAir is working with the leading environmental service and solutions provider in North America, WM to invest, improve and build upon its sustainability strategy and endeavor.
  • "The aviation industry has a great opportunity to make changes to support green initiatives and expand our sustainable practices," said Mike Bianco, CEO of AvAir.
  • Following that, AvAir will establish goals and initiatives to continue to improve its environmental impact across all channels of the company.

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, May 15, 2023
CLL, Fortress Biotech, Checkpoint, Mustang Bio, Gout, Waldenström macroglobulinemia, Dotinurad, Radiation, Arm, Triplex, Fortification, Cytomegalovirus, Chronic lymphocytic leukemia, Follicular lymphoma, Biologics license application, Fred Hutchinson Cancer Research Center, ICML, Menkes disease, CKPT, New Drug Application, Clinical trial, Lymphoma, NDA, Prescription Drug User Fee Act, Prescription, Urica, WM, CAR, Waldenström, International Conference on Afghanistan, London (2010), Patient, Risk, Hyperuricemia, PD-1, FDA, Death, BLA, Conference, Rosacea, Safety, Disease, Pharmaceutical industry, Mastic (plant resin), PDUFA

MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • In March 2023, the FDA accepted the BLA filing for cosibelimab and set a PDUFA goal date of January 3, 2024.
  • Journey Medical’s total product net revenues were $12.2 million for the first quarter of 2023, compared to first quarter 2022 total product net revenues of $20.8 million.
  • On a non-GAAP basis, Fortress research and development expenses were $2.3 million for the first quarter of 2023, compared to $2.8 million for first quarter of 2022.
  • On a non-GAAP basis, Fortress selling, general and administrative expenses were $7.0 million, for the first quarter of 2023, compared to $6.2 million for the first quarter of 2022.

Both Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Stockholders Vote “FOR” All of Broadwind’s Nominees on the Company’s WHITE Proxy Card

Retrieved on: 
Monday, May 15, 2023
Institutional Shareholder Services, Research, WM, Trustee, Glass, Environment, Broker, ISS, Security (finance), Management, CICERO

“BWEN has already booked its first win in this new environment, announcing the largest tower order in company history in January.

Key Points: 
  • “BWEN has already booked its first win in this new environment, announcing the largest tower order in company history in January.
  • The market has reacted positively to the order, operational performance has since been promising, and the analyst community has expressed a generally favorable outlook for BWEN’s prospects.”
    “[T]he dissident has presented a critique that amounts to a one-dimensional observation of historical underperformance.
  • “These recommendations reinforce our belief that the Company is heading in the right direction under its current leadership.”
    “We acknowledge with appreciation the support from the leading proxy advisory firms for all of Broadwind’s nominees,” stated Cary B.
  • Wood, Chairman of the Board.

Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Friday, May 12, 2023
CLL, Waldenström macroglobulinemia, Mayo Clinic, Arm, Chronic lymphocytic leukemia, Follicular lymphoma, Fred Hutchinson Cancer Research Center, ICML, Clinical trial, Lymphoma, Security agreement, Research, Runway, Translation, WM, Waldenström, CAR, Hematological Cancer Research Investment and Education Act, International Conference on Afghanistan, London (2010), Patient, Clinical professor, FDA, Loan, Mustang, Conference, DSM-IV codes, Safety, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
  • The final dose level escalation is anticipated in the Phase 1 indolent lymphoma arm in the third quarter of this year.
  • Research and development expenses were $14.0 million for the first quarter of 2023, compared to $16.3 million for the first quarter of 2022.
  • General and administrative expenses were $2.3 million for the first quarter of 2023, compared to $3.3 million for the first quarter of 2022.

OPAL Fuels Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, May 10, 2023
Alternative Energy, Energy, Other Energy, Oil, Gas, Emerald, ADP, British thermal unit, Electricity, GGE, Sapphire, RNG, GAAP, Ratio, Opal (fuel), Certification, WM, EPA, EBITDA, Erin, Natural gas, Prince, Growth, Transport, OPAL, Gasoline, Renewable energy, Automotive industry, Cryptocurrency, Airline, Bookkeeping, Adjustment

OPAL Fuels Inc. (“OPAL Fuels” or the “Company”) (Nasdaq: OPAL), a leading vertically integrated producer and distributor of renewable natural gas (RNG) and renewable electricity, today announced financial and operating results for the three months ended March 31, 2023.

Key Points: 
  • OPAL Fuels Inc. (“OPAL Fuels” or the “Company”) (Nasdaq: OPAL), a leading vertically integrated producer and distributor of renewable natural gas (RNG) and renewable electricity, today announced financial and operating results for the three months ended March 31, 2023.
  • “First quarter results reflect the continued progress we’ve been making on our strategic priorities,” said Co-CEO Adam Comora.
  • “First quarter results reflect the impact of lower environmental credit pricing compared to last year, and our related decision to defer monetizing the majority of our RIN inventory.
  • The Prince William RNG project is expected to commence commercial operations in the fourth quarter of 2023.